radcliffe & cardionerds @aha22: empa-kidney: empagliflozin & cv outcomes in patients with ckd
Published 1 year ago • 3.2K plays • Length 38:48Download video MP4
Download video MP3
Similar videos
-
13:07
radcliffe & cardionerds @aha22: the progressive-af trial
-
15:38
radcliffe & cardionerds @aha22: the prevent-hd randomized clinical trial
-
5:36
acc 22: results from the empulse study - empagliflozin proves beneficial for patients with hf
-
14:15
radcliffe & cardionerds @aha22: the respect epa trial
-
13:46
radcliffe & cardionerds @aha22: the ecmo-cs trial
-
4:25
esc 24: fine-heart: finerenone in hf & ckd
-
5:01
aha 22: emperor-pooled: clinical outcomes & efficacy of empagliflozin in black vs white pts with hf
-
14:21
radcliffe & cardionerds @aha22: reduction of triglycerides with pemafibrate
-
1:52
empa-kidney results: empagliflozin reduces kidney disease progression and cardiovascular deaths
-
2:56
esc 2022: the emmy trial: empagliflozin in patients with acute mi | prof harald sourji
-
18:59
radcliffe & cardionerds @aha22: the ironman trial
-
5:45
esc 2022: fidelity: finerenone in pts with chronic kidney disease | prof gerasimos filippatos
-
3:21
empa ckd - 3 min trial summary
-
10:10
empa-kidney results
-
3:35
hf 2022: deliver extends benefits of dapagliflozin to the full spectrum of pts with hf
-
3:41
jennifer green, easd 2022: finerenone & empagliflozin in patients with ckd and t2d: confidence study
-
5:14
risk for heart failure modulate the effectiveness of empagliflozin ?
-
1:06:22
empa kidney results: flozins for all ckd with dr will herrington